120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
六西格玛和统计过程控制在临床路径管理中的应用：基于变异系数、控制图和过程能力指数的评估
Authors Li KC , Zeng W, Su K, Li G
Received 23 September 2025
Accepted for publication 26 January 2026
Published 2 February 2026 Volume 2026:19 564118
DOI https://doi.org/10.2147/RMHP.S564118
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Keon-Hyung Lee
Ke-Cheng Li, Weiwei Zeng, Kangkang Su, Ge Li
Quality Control Office, Ruian People’s Hospital, Wenzhou, Zhejiang, People’s Republic of China
Correspondence: Weiwei Zeng, Email zjlkc@qq.com
Background: With the increasing emphasis on cost control and quality improvement under the Diagnosis-Related Groups (DRG) payment system, clinical pathway management has become a crucial strategy for hospitals. However, systematic, quantitative tools to assess its implementation and impact remain limited. This study explores the application value of Six Sigma-related metrics in clinical pathway management using the example of cholecystectomy for gallbladder polyps.
Methods: Hospitalization costs and length of stay were used as evaluation indicators. Six Sigma-related parameters, including the coefficient of variation, Statistical Process Control (SPC) control charts, and process performance indices, were employed to assess the differences before and after the implementation of the clinical pathway.
Results: After implementation of the clinical pathway, the average total cost significantly decreased from ¥ 10,509± 1457 to ¥ 9998.4 ± 1370.7 (P < 0.001), and the mean LOS reduced from 4.64± 1.47 to 3.90 ± 1.08 days (P < 0.001). Process stability improved markedly, with the CV for cost and LOS dropping from 0.139 to 0.137 and 0.317 to 0.278, respectively. The Ppk for total cost rose from 0.46 to 0.67, corresponding to a reduction in the expected defective rate from 82,101.71 to 21,779.86 Parts Per Million (PPM). SPC control charts demonstrated narrowed control limits and enhanced process precision, indicating that clinical variability was effectively suppressed.
Conclusion: Integrating Six Sigma into clinical pathway management provides a robust approach to enhance healthcare delivery under Diagnosis-Related Group(DRG) constraints. Hospital administrators can leverage Statistical Process Control charts for real-time monitoring and train staff in Six Sigma to improve care consistency, while policymakers can establish healthcare-specific process performance benchmarks to advance quality and payment reforms. This method bridges industrial quality control with healthcare, offering scalable benefits for system efficiency and equity.
Keywords: six sigma, statistical process control, process performance index, clinical pathway coefficient of variation, gallbladder polyps
Quality Control Office, Ruian People’s Hospital, Wenzhou, Zhejiang, People’s Republic of China
Correspondence: Weiwei Zeng, Email zjlkc@qq.com
Background: With the increasing emphasis on cost control and quality improvement under the Diagnosis-Related Groups (DRG) payment system, clinical pathway management has become a crucial strategy for hospitals. However, systematic, quantitative tools to assess its implementation and impact remain limited. This study explores the application value of Six Sigma-related metrics in clinical pathway management using the example of cholecystectomy for gallbladder polyps.
Methods: Hospitalization costs and length of stay were used as evaluation indicators. Six Sigma-related parameters, including the coefficient of variation, Statistical Process Control (SPC) control charts, and process performance indices, were employed to assess the differences before and after the implementation of the clinical pathway.
Results: After implementation of the clinical pathway, the average total cost significantly decreased from ¥ 10,509± 1457 to ¥ 9998.4 ± 1370.7 (P < 0.001), and the mean LOS reduced from 4.64± 1.47 to 3.90 ± 1.08 days (P < 0.001). Process stability improved markedly, with the CV for cost and LOS dropping from 0.139 to 0.137 and 0.317 to 0.278, respectively. The Ppk for total cost rose from 0.46 to 0.67, corresponding to a reduction in the expected defective rate from 82,101.71 to 21,779.86 Parts Per Million (PPM). SPC control charts demonstrated narrowed control limits and enhanced process precision, indicating that clinical variability was effectively suppressed.
Conclusion: Integrating Six Sigma into clinical pathway management provides a robust approach to enhance healthcare delivery under Diagnosis-Related Group(DRG) constraints. Hospital administrators can leverage Statistical Process Control charts for real-time monitoring and train staff in Six Sigma to improve care consistency, while policymakers can establish healthcare-specific process performance benchmarks to advance quality and payment reforms. This method bridges industrial quality control with healthcare, offering scalable benefits for system efficiency and equity.
Keywords: six sigma, statistical process control, process performance index, clinical pathway coefficient of variation, gallbladder polyps